Serum p97 levels as an aid to identifying Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 3, Issue 5, 2001, Pages 507-516

  Feldman, H ^a   Gabathuler, R ^b   Kennard, M ^c   Nurminen, J ^d   Levy, D ^e   Foti, S ^a   Foti, D ^a   Beattie, B L ^b   Jefferies, W A ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Departments of Medical Genetics   (Canada)

^d Synapse Technologies Inc   (Canada)

^e Stat/Epidemiol Res Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEIN P97; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; HUMAN; LABORATORY DIAGNOSIS; MICROGLIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 0034755276     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2001-3510     Document Type: Article

References (43)

1. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study
2. Assessing dementia: The Canadian consensus. Organizing Committee, Canadian Consensus Conference on the Assessment of Dementia
3. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abetal-42/1 ratio in vitro and in vivo
4. Neuropathological stageing of Alzheimer-related changes
5. Canadian study of health and aging: Study methods and prevalence of dementia
6. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers
7. Clinical and neuropathological criteria for frontotemporal dementia
8. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" Neurobiol Aging
9. The assessment of everyday functioning using the present functioning questionnaire and the functional rating scale in elderly samples
10. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease
11. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD
12. Cognitive impairment in the nondemented elderly. Results from the Canadian study of health and aging
13. The Functional Rating Scale (FRS) in Alzheimer's disease: A longitudinal study
14. Serum levels of the iron binding protein p97: A novel biological marker of Alzheimer's disease
15. Mini-mental state, A practical method for grading the cognitive state of patients for the clinician
16. Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein
17. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
18. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia
19. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
20. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease
21. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin
22. Controlled process to recover heterologous glycosylphosphatidylinositol membrane anchored proteins from CHO cells
23. A novel iron uptake mechanism mediated by GPI-anchored human p97
24. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease
25. Diffuse type of Lewy body disease: Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - A new disease?
26. Cerebrospinal fluid of patients with senile dementia of Alzheimer's type shows an increased inhibition of alphachymotrypsin
27. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging
28. Anti-inflammatory drugs and Alzheimer-type pathology in aging
29. Neuropathological criteria for the diagnosis of Alzheimer's disease
30. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia
31. Community screening for dementia: The Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared
32. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT)
33. Consensus criteria for the clinical diagnosis of dementia with Lewy bodies
34. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
35. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
36. Use of p97 (melanotransferrin) in the diagnosis of Alzheimer's disease
37. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly
38. Soluble amyloid beta- protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls
39. Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research concensus statement
40. Coincident expression and distribution of melanotransferin and transferrin receptor in human brain capillary endothelium
41. Elevation of CSF tau in early stage Alzheimer's disease
42. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease
43. The Modified Mini-Mental State (3MS) examination